Another strength is that this drug is the first specific drug in the world that can treat COVID-19 infection.
COVID-19 has been raging around the world since the end of 20 19, which has brought a devastating blow to countless families. In the face of such a severe global anti-epidemic situation, every kind person is extremely worried. After three years, the anti-epidemic situation has improved, but it has not been completely solved, which has also made the already pessimistic global economic situation worse.
Since 19, countless medical scientists have devoted all their energy to the research and development of vaccines and therapeutic drugs day and night in order to conquer COVID-19, regardless of their personal safety. Professor Zhang, director of Tsinghua University Medical College and Center for Global Health and Infectious Diseases, led the R&D team to take the lead in developing a specific drug that can be treated, and obtained the approval for listing in China, which also marked that our country was at the forefront in the fight against it.
Brief introduction and characteristics of domestic COVID-19 specific drugs
First, pharmacological effects.
According to Professor Zhang, this specific drug, Ambavirumab/Romisimab combination therapy, is mainly administered by intravenous drip, and it will take effect 40 minutes after drip. Its pharmacology is to treat COVID-19 by injecting two kinds of COVID-19 blocking antibodies. In short, this drug can stimulate the patient's resistance and produce immunity to the virus. More importantly, the two antibodies injected into patients can remain in patients for nine to twelve months, that is, during this period, COVID-19 infection can be continuously prevented.
Second, the characteristics and significance
1, function
The characteristic of COVID-19 specific medicine made in China is that it can not only treat patients who have been infected with COVID-19 virus, but also effectively prevent COVID-19 virus infection in 9 to 12 months. In other words, it can not only treat COVID-19, but also prevent COVID-19.
2. Significance
The most important significance is that the domestic COVID-19 specific drug is the first specific drug to treat and resist COVID-19 in the world, and it is a drug with complete intellectual property rights and independent research and development.
The first anti-COVID-19 antibody specific drug independently developed and proved to be effective in China.
The combination therapy of domestic COVID-19 specific drug Ambaviruzumab/Romisizumab can not only treat COVID-19, but also prevent it. It can reduce the hospitalization rate and mortality rate of high-risk outpatients by 80%. How strong!